Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/120009
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Basal insulin and cardiovascular and other outcomes in dysglycemia
Author: Gerstein, H.
Bosch, J.
Dagenais, G.
Díaz, R.
Jung, H.
Maggioni, A.
Pogue, J.
Probstfield, J.
Ramachandran, A.
Riddle, M.
Rydén, L.
Yusuf, S.
Richardson, L.
Diaz, R.
Johnston, P.
Vige, R.
Birkeland, K.
Budaj, A.
Cardona, E.
Chazova, I.
et al.
Citation: New England Journal of Medicine, 2012; 367(4):319-328
Publisher: Massachusetts Medical Society
Issue Date: 2012
ISSN: 0028-4793
1533-4406
Statement of
Responsibility: 
Hertzel C. Gerstein, Jackie Bosch, Gilles R. Dagenais, Rafael Díaz, Aldo P. Maggioni, Janice Pogue
Abstract: BACKGROUND: The provision of sufficient basal insulin to normalize fasting plasma glucose levels may reduce cardiovascular events, but such a possibility has not been formally tested. METHODS: We randomly assigned 12,537 people (mean age, 63.5 years) with cardiovascular risk factors plus impaired fasting glucose, impaired glucose tolerance, or type 2 diabetes to receive insulin glargine (with a target fasting blood glucose level of ≤95 mg per deciliter [5.3 mmol per liter]) or standard care and to receive n-3 fatty acids or placebo with the use of a 2-by-2 factorial design. The results of the comparison between insulin glargine and standard care are reported here. The coprimary outcomes were nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes and these events plus revascularization or hospitalization for heart failure. Microvascular outcomes, incident diabetes, hypoglycemia, weight, and cancers were also compared between groups. RESULTS: The median follow-up was 6.2 years (interquartile range, 5.8 to 6.7). Rates of incident cardiovascular outcomes were similar in the insulin-glargine and standard-care groups: 2.94 and 2.85 per 100 person-years, respectively, for the first coprimary outcome (hazard ratio, 1.02; 95% confidence interval [CI], 0.94 to 1.11; P=0.63) and 5.52 and 5.28 per 100 person-years, respectively, for the second coprimary outcome (hazard ratio, 1.04; 95% CI, 0.97 to 1.11; P=0.27). New diabetes was diagnosed approximately 3 months after therapy was stopped among 30% versus 35% of 1456 participants without baseline diabetes (odds ratio, 0.80; 95% CI, 0.64 to 1.00; P=0.05). Rates of severe hypoglycemia were 1.00 versus 0.31 per 100 person-years. Median weight increased by 1.6 kg in the insulin-glargine group and fell by 0.5 kg in the standard-care group. There was no significant difference in cancers (hazard ratio, 1.00; 95% CI, 0.88 to 1.13; P=0.97). CONCLUSIONS: When used to target normal fasting plasma glucose levels for more than 6 years, insulin glargine had a neutral effect on cardiovascular outcomes and cancers. Although it reduced new-onset diabetes, insulin glargine also increased hypoglycemia and modestly increased weight. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Keywords: ORIGIN Trial Investigators
Rights: © 2012 Massachusetts Medical Society.
RMID: 0030107846
DOI: 10.1056/NEJMoa1203858
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.